Nivolumab and ipilimumab improve PFS in newly diagnosed metastatic colorectal cancer
The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) improved progression-free survival (PFS) by blinded independent central review (BICR) compared to the chemotherapy chosen by investigators as front-line treatment for microsatellite patients. resulted in statistically significant and clinically meaningful improvements in Meets one of the two primary endpoints of the Phase 3 CheckMate-8HW study in unstable-high […]
Superior PFS with sotorasib in colorectal cancer
Metastatic colorectal cancer (CRC) patients with KRAS (G12C) mutations benefit from sotorasib plus panitumumab Kirsten rat sarcoma viral oncogene homologs are present in approximately 3% of all metastatic colorectal tumors (class) gly12-to-cys (G12C) mutation. Associated with poor prognosis.1 Sotorasib is a selective KRAS inhibitor that targets proteins derived from KRAS. class (G12C) mutation. In the […]
Lumakras Plus Vectibix improves PFS in colorectal cancer
Patients with colorectal cancer had improved progression-free survival with the combination of Lumaclas and Vectibix. Treatment with Lumaclas (sotorasib) in combination with Vectibix (panitumumab) at multiple dose levels significantly increases patient progression-free survival (PFS) and disease progression from random assignment in clinical trials compared to standard of care (SOC). (time to progression or death).Have chemotherapy-resistant […]